Turn Therapeutics Inc. (TTRX) — SEC Filings
Turn Therapeutics Inc. (TTRX) — 15 SEC filings. Latest: 4 (Apr 3, 2026). Includes 7 8-K, 2 EFFECT, 2 S-1.
View Turn Therapeutics Inc. on SEC EDGAR
Overview
Turn Therapeutics Inc. (TTRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 3, 2026: Turn Therapeutics Inc. filed an EFFECT form on April 3, 2026, indicating the effectiveness of a registration statement related to securities. The filing, with accession number 9999999995-26-001065, pertains to Act 33 and File No. 333-290800, with an effectiveness date of April 2, 2026.
Sentiment Summary
Across 15 filings, the sentiment breakdown is: 3 bearish, 9 neutral, 3 mixed. The dominant filing sentiment for Turn Therapeutics Inc. is neutral.
Filing Type Overview
Turn Therapeutics Inc. (TTRX) has filed 1 4, 2 EFFECT, 7 8-K, 1 10-Q, 2 S-1, 2 S-1/A with the SEC between Sep 2025 to Apr 2026.
Filings by Year
Recent SEC Filings (15)
Risk Profile
Risk Assessment: Of TTRX's 11 recent filings, 5 were flagged as high-risk, 2 as medium-risk, and 4 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | $ -3.47M |
| EPS | $ -0.13 |
| Debt-to-Equity | N/A |
| Cash Position | $ 3.11M |
| Operating Margin | N/A |
| Total Assets | $ 4.30M |
| Total Debt | $ 3.79M |
Key Executives
- Bradley Burnam
- Michael Kaplan
- Stephen A. Byeff
- Erin Koprince, MA
- Dr. Dan Davis
Industry Context
Turn Therapeutics operates in the pharmaceutical and medical device development sector, focusing on dermatological diseases and intranasal vaccines. The company leverages proprietary platform technology (PermaFusion) to enhance drug performance. The sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles from bodies like the FDA.
Top Tags
Biotechnology (5) · Dermatology (5) · Pharmaceuticals (4) · Medical Devices (4) · Direct Listing (4) · Emerging Growth Company (4) · corporate-action (3) · filing (2) · name-change (2) · S-1 Filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Effectiveness Date | 2026-04-02 | The date the registration statement became effective. |
| Filing Date | 2026-04-03 | The date the filing was accepted by the SEC. |
| Net Loss | $3.47M | for the nine months ended September 30, 2025, a 140.7% increase from $1.45M in 2024 |
| Cash and Cash Equivalents | $3.11M | as of September 30, 2025, up from $0.87M at December 31, 2024 |
| Accumulated Deficit | $22.67M | as of September 30, 2025, indicating significant historical losses |
| General and Administrative Expenses | $3.43M | for the nine months ended September 30, 2025, more than double the $1.23M in 2024 |
| Negative Cash Flows from Operations | $1.39M | for the nine months ended September 30, 2025, worsening from $0.93M in 2024 |
| Proceeds from Common Stock Issuance | $3.74M | net of issuance costs, for the nine months ended September 30, 2025 |
| Shares of Common Stock Outstanding | 29,445,183 | as of November 12, 2025, after a 2-for-1 forward stock split |
| Cash Runway | Q1 2026 | estimated period cash and cash equivalents will fund operations |
| SEC File Number | 001-42875 | Identifies the company's filing history |
| IRS Employer Identification Number | 32-0456090 | Company's tax identification number |
| Aggregate purchase price | $85,000,000 | Committed equity financing from GEM under the GEM Purchase Agreement |
| Shares of common stock | 7,000,000 | Maximum number of shares offered by selling stockholders in this S-1 |
| Closing price per share | $7.00 | Closing price of TTRX common stock on Nasdaq on October 8, 2025 |
Frequently Asked Questions
What are the latest SEC filings for Turn Therapeutics Inc. (TTRX)?
Turn Therapeutics Inc. has 15 recent SEC filings from Sep 2025 to Apr 2026, including 7 8-K, 2 EFFECT, 2 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TTRX filings?
Across 15 filings, the sentiment breakdown is: 3 bearish, 9 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Turn Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Turn Therapeutics Inc. (TTRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Turn Therapeutics Inc.?
Key financial highlights from Turn Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TTRX?
The investment thesis for TTRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Turn Therapeutics Inc.?
Key executives identified across Turn Therapeutics Inc.'s filings include Bradley Burnam, Michael Kaplan, Stephen A. Byeff, Erin Koprince, MA, Dr. Dan Davis.
What are the main risk factors for Turn Therapeutics Inc. stock?
Of TTRX's 11 assessed filings, 5 were flagged high-risk, 2 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Turn Therapeutics Inc.?
Forward guidance and predictions for Turn Therapeutics Inc. are extracted from SEC filings as they are enriched.